AB001

About Vopec Pharmaceuticals

Indian biotech leveraging traditional medicine to create low‑toxicity small‑molecule oncology drugs and CDMO services.

About Agastiya Biotech

Agastiya Biotech is an early-stage, private biotech focused on developing novel small molecule oncology therapeutics through a unique platform combining AI, quantum biology, and ancient medical knowledge. Its lead candidate, AB001, has completed a Phase I trial showing promising efficacy and a strong safety profile, with Phase II trials now underway in India. The company's ambitious strategy targets high-value areas like pan-KRAS inhibition and cancer stem cell eradication with a single oral agent, positioning it in a competitive but potentially lucrative oncology market. Its success hinges on validating its novel mechanisms and advancing clinical development.

Therapeutic Areas